LVGO - How Amazon Is Shaking Up Telemedicine Plus 1 Winner and 1 Loser Exiting ESMO
Every fall, pharmaceutical industry leaders, clinicians, and interested observers of all stripes gather at the annual European Society for Medical Oncology (ESMO) Congress to discuss the latest news in the ongoing attempts to cure various types of cancer. This year, a number of companies unveiled market-moving data from cancer drug trials at the event. However, it was arguably Seattle Genetics (NASDAQ: SGEN) that was the conference's biggest winner, and Amgen (NASDAQ: AMGN) that was its biggest loser.
In this episode of The Motley Fool's Industry Focus: Healthcare, host Shannon Jones is joined by contributor Todd Campbell to explain how Seattle Genetics could reshape how doctors treat bladder cancer, and why Amgen's promising KRAS-targeting drug candidate, AMG 510, appears to be falling short of expectations.
Also, Jones and Campbell weigh in on Amazon's (NASDAQ: AMZN) latest attempt to rein in runaway healthcare costs by launching a virtual health program for its workers. Here's why Amazon's making this move, and why it may not be bad news for telemedicine leader Teladoc (NYSE: TDOC).